Replimune reports Q1 FY2026 net loss $86.7M; FDA issues CRL for RP1 BLA

Replimune Group, Inc.

2026-Q1 EPS reported -$0.95

Net loss of $86.7M for quarter ended June 30, 2025, vs $53.8M a year ago.
Cash, cash equivalents and short-term investments $403.3M; funding expected into Q4 2026.
FDA issued Complete Response Letter for RP1 BLA in advanced melanoma on July 22, 2025.
R&D expenses $57.8M (up from $43.0M); SG&A $32.6M (up from $14.4M), driven by commercial prep.
Ongoing Phase 3 IGNYTE-3 trial for RP1+nivolumab; Phase 2/3 REVEAL trial for RP2 in uveal melanoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.